China Generic Drug Makers Set For Bumper Harvest As Patents Expire
This article was originally published in PharmAsia News
Executive Summary
In 2007, some 35 drugs around the world lost their patent protection. For makers of generics, this presents an $82 billion opportunity. Industry experts see China's drug manufacturers having an edge thanks to their lower production and environmental protection costs, as well as strong ability to clone original products. At the same time, local enterprises face hurdles in the poorer quality of their generic drugs, low-level research and development, and inadequate understanding of the international market. The last shortcoming stems from the language gap in communication, the brief experience of the local industry in globalization, and limited exposure to overseas investment. (Click here for more)